PT. RICHMOND, Calif., March 19 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. today announced that Glenn A. Oclassen, Chief Executive Officer & President, will present at the BioCentury "Future Leaders in the Biotech Industry" Conference at the Millennium Broadway Hotel & Conference Center in New York City on Thursday, March 27, 2008 at 9:30 AM Eastern Time.
About Transcept Pharmaceuticals
Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company
deriving significant new patient benefits from proven CNS drugs. Transcept
development projects leverage new understanding of CNS conditions to
provide additional uses and enhanced clinical benefits for existing active
agents. The lead Transcept product candidate, Intermezzo(R) (zolpidem
tartrate lozenge), is a low dose sublingual formulation of zolpidem for the
treatment of insomnia in patients who awaken in the middle of the night and
have difficulty returning to sleep. Phase 3 clinical trials have been
completed for Intermezzo(R) and Transcept plans to submit an NDA in the
third quarter of 2008. Transcept is also developing TO-2060, a novel,
fixed-dose combination of olanzapine and ondansetron for the treatment of
dopamine associated psychiatric disorders. For further information, please
visit the company's website at: http://www.transcept.com.
Transcept Pharmaceuticals, Inc.
Director of Communications
The Ruth Group
Investors / Media
Stephanie Carrington / Jason Rando
(646) 536-7017 / 7025
|SOURCE Transcept Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved